Boston Scientific Corporation (NYSE:BSX) – Equities research analysts at Wedbush decreased their FY2018 EPS estimates for Boston Scientific in a research note issued on Thursday. Wedbush analyst Levy. T now expects that the medical equipment provider will post earnings per share of $1.34 for the year, down from their prior estimate of $1.37. Wedbush also issued estimates for Boston Scientific’s FY2019 earnings at $1.46 EPS and FY2020 earnings at $1.60 EPS.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period in the prior year, the business posted $0.27 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year.
Boston Scientific (BSX) traded down $0.13 during trading hours on Friday, reaching $26.15. 16,183,181 shares of the company were exchanged, compared to its average volume of 6,852,641. Boston Scientific has a 52 week low of $20.03 and a 52 week high of $29.93. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. The company has a market cap of $35,910.00, a price-to-earnings ratio of 21.63, a P/E/G ratio of 2.04 and a beta of 0.99.
A number of institutional investors have recently modified their holdings of the business. Comerica Securities Inc. grew its position in shares of Boston Scientific by 0.9% in the 2nd quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock worth $318,000 after buying an additional 99 shares during the period. ETRADE Capital Management LLC grew its position in shares of Boston Scientific by 1.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock worth $279,000 after buying an additional 171 shares during the period. Krilogy Financial LLC grew its position in shares of Boston Scientific by 5.9% in the 2nd quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock worth $213,000 after buying an additional 430 shares during the period. Wetherby Asset Management Inc. grew its position in shares of Boston Scientific by 3.9% in the 2nd quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock worth $382,000 after buying an additional 523 shares during the period. Finally, Greenwood Capital Associates LLC grew its position in shares of Boston Scientific by 1.1% in the 2nd quarter. Greenwood Capital Associates LLC now owns 53,330 shares of the medical equipment provider’s stock worth $1,478,000 after buying an additional 564 shares during the period. 90.55% of the stock is currently owned by institutional investors and hedge funds.
In other Boston Scientific news, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $28.72, for a total transaction of $445,160.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of Boston Scientific stock in a transaction on Tuesday, November 28th. The shares were bought at an average cost of $0.45 per share, for a total transaction of $183,602.70. Over the last three months, insiders have sold 414,698 shares of company stock worth $12,013,153. Insiders own 0.74% of the company’s stock.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.